Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.2
Q1 in SJR 2025, SJR score – 0.599, H-index: 54 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

Ahead of print

doi: 10.17219/acem/130592

Publication type: review article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Does the choice of drug in pharmacologic cardioversion correlate with the guidelines? Systematic review

Janusz Springer1,A,B,C,D,E,F, Tomasz Szmuda2,B,C,D,E,F, Dariusz Kozłowski3,A,E,F

1 Department of Emergency Medicine, Medical University of Gdańsk, Poland

2 Department of Neurosurgery, Medical University of Gdańsk, Poland

3 Department of Cardiology and Electrotherapy, Medical University of Gdańsk, Poland

Abstract

Background. Atrial fibrillation (AF) is the most common sustained arrhythmia, the most common cause of supraventricular tachycardia in the global population and the most common arrhythmia requiring treatment in an emergency department.
Objectives. To systematically review recent literature and quantify the correlation between the choice of pharmacological cardioversion (PCV) drug and the national or international guidelines.
Material and Methods. A systematic review was performed in accordance with the PRISMA statement methodology. The PubMed search engine was used to search for articles regardless of type or language and published in the last 6 years (May 2014–May 2020). In addition, we searched for AF guidelines and recommendations published online by cardiology and emergency medicine societies.
Results. The search strategy returned a total of 2615 abstracts. A total of 2598 full texts were screened; 2540 full texts were excluded with reasons and 58 articles from 32 countries were included in the analysis. In 17 of the 58 articles (29%), we noted discrepancies with the AF guidelines, specifically regarding the PCV drug used, the patients’ comorbidities and the contraindications associated with the PCV drug. The most common clinical situation for the use of a contraindicated drug was when ibutilide was administered to patients with heart failure. The analysis did not reveal any statistically significant correlations, although the correlation between the sample size and guideline adherence was close to statistical significance (p < 0.06).
Conclusion. Our systematic analysis revealed substantial non-adherence to AF treatment guidelines.

Key words

atrial fibrillation, cardioversion, guideline adherence, antiarrhythmic

References (82)

  1. Chung MK, Eckhardt LL, Chen LY, et al. Lifestyle and risk factor modification for reduction of atrial fibrillation: A scientific statement from the American Heart Association. Circulation. 2020;141(16):e750–e772. https://doi.org/10.1161/CIR.0000000000000748
  2. Kozłowski D. Method in the chaos: A step-by-step approach to ECG interpretation. Eur J Transl Clin Med. 2018;1(1):76–92. doi:10.31373/ejtcm/92255
  3. Stiell IG, Sivilotti ML, Taljaard M, et al. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): A partial factorial randomised trial. Lancet. 2020;395(10221):339–349. doi:10.1016/S0140-6736(19)32994-0
  4. Kozlowski D, Budrejko S, Lip GY, et al. Lone atrial fibrillation: What do we know? Heart. 2010;96(7):498–503. doi:10.1136/hrt.2009.176321
  5. Hindricks G, Potpara T, Dagres N, et al; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498. doi:10.1093/eurheartj/ehaa612
  6. Rogenstein C, Kelly AM, Mason S, et al. An international view of how recent‐onset atrial fibrillation is treated in the emergency department. Acad Emerg Med. 2012;19(11):1255–1260. doi:10.1111/acem.12016
  7. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097
  8. Brieger D, Amerena J, Attia JR, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Med J Aust. 2018;209(8):356–362. https://doi.org/10.5694/mja18.00646.
  9. Stiell IG, Scheuermeyer FX, Vadeboncoeur A, et al. CAEP acute atrial fibrillation/flutter best practices checklist. Can J Emerg Med. 2018;20(3):334–342. https://doi.org/10.1017/cem.2018.26
  10. Andrade JG, Verma A, Mitchell LB, et al. 2018 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol. 2018;34(11):1371–1392. doi:10.1016/j.cjca.2018.08.026
  11. Soar J, Nolan JP, Böttiger BW, et al. European Resuscitation Council Guidelines for Resuscitation 2015: Section 3. Adult advanced life support. Resuscitation. 2015;95:100–147. doi:10.1016/j.resuscitation.2015.07.016
  12. National Institute for Health and Care Excellence (NICE). Atrial fibrillation: Management. Clinical guideline. London, UK: NICE; 2014. https://www.nice.org.uk/guidance/cg180/resources/atrial-fibrillation-management-pdf-35109805981381. Accessed June 5, 2020.
  13. Baugh C, Pate K, Brooks JA, et al. An evidence-driven tool to guide the selection and management of emergency department patients with atrial fibrillation and atrial flutter. Irving, USA: American College of Emergency Physicians. 2018. https://www.acep.org/patient-care/afib/. Accessed June 5, 2020.
  14. January CT, Wann LS, Alpert JS, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–2104. doi:10.1161/CIR.0000000000000040
  15. Albakri A, Klingenheben T. Unusual severe hemodynamic failure associated with standard dose of intravenous flecainide for pharmacological cardioversion of atrial fibrillation. HeartRhythm Case Rep. 2017;3(9):440–442. doi:10.1016/j.hrcr.2017.07.003
  16. Amin AS, Peters RH, Verstraaten M, Wilde AA, Buijs EM. Baseline NT-ProBNP level predicts success of cardioversion of atrial fibrillation with flecainide. Netherlands Heart J. 2015;23(3):182–189. doi:10.1007/s12471-015-0659-8
  17. Andrade JG, MacGillivray J, Macle L, et al. Clinical effectiveness of a systematic “pill-in-the-pocket” approach for the management of paroxysmal atrial fibrillation. Heart Rhythm. 2018;15(1):9–16. doi:10.1016/j.hrthm.2017.10.002
  18. Balik M, Kolnikova I, Maly M, Waldauf P, Tavazzi G, Kristof J. Propafenone for supraventricular arrhythmias in septic shock: Comparison to amiodarone and metoprolol. J Crit Care. 2017;41:16–23. doi:10.1016/j.jcrc.2017.04.027
  19. Balsam P, Koźluk E, Peller M, et al. Antazoline for termination of atrial fibrillation during the procedure of pulmonary veins isolation. Adv Med Sci. 2015;60(2):231–235. doi:10.1016/j.advms.2015.03.002
  20. Beatch GN, Bhirangi K, Juul-Moller S, Rustige J. Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation in the Asia-Pacific region: A phase 3 randomized controlled trial. J Cardiovasc Pharmacol. 2017;69(2):86–92. doi:10.1097/FJC.0000000000000445
  21. Bonora A, Turcato G, Franchi E, et al. Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: A propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs. Intern Emerg Med. 2017;12(6):853–859. doi:10.1097/FJC.0000000000000445
  22. Carbajosa DJ, Cosin-Sales J, Pérez-Durá MJ, et al. Vernakalant in hospital emergency practice: Safety and effectiveness [in Spanish]. Emergencias. 2017;29(6):397. PMID:29188914
  23. Champion S, Gaüzère BA, Vandroux D, Lefort Y. Is it worth delivering direct-current counter shock to critically ill patients with supra-ventricular tachyarrhythmia? [in French]. Ann Cardiol Angeiol (Paris). 2018;67(4):260–263. doi:10.1016/j.ancard.2018.04.003
  24. Chauveau S, Le Vavasseur O, Morel E, Dulac A, Chevalier P. Flecainide is a safe and effective treatment for pre-excited atrial fibrillation rapidly conducted to the ventricle in pregnant women: A case series. Eur Heart J Case Rep. 2019;3(2):ytz066. doi:10.1093/ehjcr/ytz066
  25. Comelli I, Pigna F, Cervellin G. 1:1 atrial flutter induced by flecainide, whilst the patient was at rest. Am J Emerg Med. 2018;36(11):2131.e3–2131.e5. doi:10.1016/j.ajem.2018.07.040
  26. Cosin-Sales J, Loscos A, Peiró A, Sorando MR, Buendía F, Ruescas L. Real-world data on the efficacy of vernakalant for pharmacological cardioversion in patients with recent-onset atrial fibrillation. Rev Esp Cardiol (Engl Ed). 2016;69(6):619–620. doi:10.1016/j.rec.2016.02.020
  27. Costabel JP, Lambardi F, Aragon M, et al. Predictors of conversion of recent‐onset atrial fibrillation treated with vernakalant. Pacing Clin Electrophysiol. 2015;38(2):196–200. doi:10.1111/pace.12548
  28. Dalyanoglu H, Mehdiani A, Minol JP, et al. Conversion of atrial fibrillation after cardiosurgical procedures by Vernakalant® as an atrial repolarization delaying agent (ARDA). Heart Surg Forum. 2018;21(3):E201–E208. doi:10.1532/hsf.1970
  29. Dasgupta S, Dave I, Whitehill R, Fischbach P. Chemical cardioversion of atrial flutter and fibrillation in the pediatric population with ibutilide. Pacing Clin Electrophysiol. 2020;43(3):322–326. doi:10.1111/pace.13890
  30. Dilber D, Čerkez-Habek J, Barić H, Gradišer M. Atrial fibrillation cardioversion following acupuncture. Saudi Med J. 2015;36(11):1351–1353. doi:10.15537/smj.2015.11.12891
  31. Dong Z, Yao H, Miao Z, et al. Pretreatment with intravenous amiodarone improves the efficacy of ibutilide treatment on cardioversion rate and maintenance time of sinus rhythm in patients with persistent atrial fibrillation. Biomed Rep. 2017;6(6):686–690. doi:10.3892/br.2017.896
  32. Farkowski MM, Maciąg A, Żurawska M, et al. Comparative effectiveness and safety of antazoline-based and propafenone-based strategies for pharmacological cardioversion of short-duration atrial fibrillation in the emergency department. Pol Arch Med Wewn. 2016;126(6):381–387. doi:10.20452/pamw.3452
  33. Farkowski MM, Maciag A, Zurawska M, Kowalik I, Szwed H, Pytkowski M. Clinical effectiveness and safety of antazoline‐based therapy in patients with stable coronary artery disease undergoing pharmacological cardioversion of short‐duration atrial fibrillation in the emergency department. Cardiovasc Ther. 2018;36(6):e12469. doi:10.1111/1755-5922.12469
  34. Farkowski MM, Maciag A, Kowalik I, Konka M, Szwed H, Pytkowski M. Intravenous antazoline, a first‐generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio‐venous conduction and high clinical effectiveness (AntaEP Study). Brit J Clin Pharmacol. 2019;85(7):1552–1558. doi:10.1111/bcp.13940
  35. Gillinov AM, Bagiella E, Moskowitz AJ, et al. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med. 2016;374(20):1911–1921. doi:10.1056/NEJMoa1602002
  36. Hamilton A, Clark D, Gray A, Cragg A, Grubb N. The epidemiology and management of recent-onset atrial fibrillation and flutter presenting to the emergency department. Eur J Emerg Med. 2015;22(3):155–161. doi:10.1097/MEJ.0000000000000198
  37. Kapelios CJ, Bonou MS, Diamantopoulos P, et al. Ibrutinib-related atrial fibrillation: Therapeutic challenges. J Oncol Pharm Pract. 2019;25(5):1258–1260. doi:10.1177/1078155218785983
  38. Karavelioğlu Y, Karapınar H, Yüksel M, et al. Neutrophil to lymphocyte ratio is predictor of atrial fibrillation recurrence after cardioversion with amiodarone. Clin Appl Thromb Hemost. 2015;21(1):5–9. doi:10.1177/1076029613518368
  39. Kriz R, Freynhofer MK, Weiss TW, et al. Safety and efficacy of pharmacological cardioversion of recent-onset atrial fibrillation: A single-center experience. Am J Emerg Med. 2016;34(8):1486–1490. doi:10.1016/j.ajem.2016.05.012
  40. Lewis G, Currie P. Atrial fibrillation during pregnancy: Cardioversion with flecainide. Brit J Hosp Med (Lond). 2015;76(12):720–721. doi:10.12968/hmed.2015.76.12.720
  41. Liberman L, Starc TJ, Silver ES. Usefulness of high-dose oral flecainide for termination of recent-onset atrial fibrillation in children. Am J Cardiol. 2018;121(12):1530–1533. doi:10.1016/j.amjcard.2018.03.001
  42. Maciag A, Farkowski MM, Chwyczko T, et al. Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study). Europace. 2017;19(10):1637–1642. doi:10.1093/europace/euw384
  43. Maimone S, Filomia R, Saitta C, Raimondo G, Squadrito G. Case report: Atrial fibrillation after intravenous administration of iodinated contrast medium in a patient with hepatocellular carcinoma. Medicine (Baltimore). 2015;94(35):e1406. doi:10.1097/MD.0000000000001406
  44. Manolis AS, Bethanis S, Metaxa S, Polytarchou K, Sakellaris N, Pyrros I. Use of intravenous vernakalant for atrial fibrillation conversion in the regular ward under only bedside monitoring. Hellenic J Cardiol. 2019;60(1):54–56. doi:10.1016/j.hjc.2018.02.003
  45. Mansoor E. De novo atrial fibrillation post cardiac surgery: The Durban experience. Cardiovasc J Afr. 2014;25(6):282. doi:10.5830/CVJA-2014-067
  46. Milojevic K, Beltramini A, Nagash M, Muret A, Richard O, Lambert Y. Esmolol compared with amiodarone in the treatment of recent-onset atrial fibrillation (RAF): An emergency medicine external validity study. J Emerg Med. 2019;56(3):308–318. doi:10.1016/j.jemermed.2018.12.010
  47. Mitrić G, Udy A, Bandeshe H, Clement P, Boots R. Variable use of amio­darone is associated with a greater risk of recurrence of atrial fibrillation in the critically ill. Crit Care. 2016;20(1):1–9. doi:10.1186/s13054-016-1252-2
  48. Mochalina N, Juhlin T, Öhlin B, Carlson J, Holmqvist F, Platonov PG. Predictors of successful cardioversion with vernakalant in patients with recent‐onset atrial fibrillation. Ann Noninvasive Electrocardiol. 2015;20(2):140–147. doi:10.1111/anec.12178
  49. Nemati MH, Astaneh B. Amiodarone versus propafenone to treat atrial fibrillation after coronary artery bypass grafting: A randomized double blind controlled trial. Korean J Thorac Cardiovasc Surg. 2016;49(3):177–184. doi:10.5090/kjtcs.2016.49.3.177
  50. Pluymaekers NA, Dudink EA, Luermans JG, et al. Early or delayed cardioversion in recent-onset atrial fibrillation. N Engl J Med. 2019;380(16):1499–1508. doi:10.1056/NEJMoa1900353
  51. Pohjantähti-Maaroos H, Hyppölä H, Lekkala M, Sinisalo E, Heikkola A, Hartikainen J. Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation. Eur Heart J Acute Cardiovasc Care. 2019;8(2):114–120. doi:10.1177/2048872617728558
  52. Rudiger A, Breitenstein A, Arrigo M, Salzberg SP, Bettex D. Suitability, efficacy, and safety of vernakalant for new onset atrial fibrillation in critically ill patients. Crit Care Res Pract. 2014;2014:826286. doi:10.1155/2014/826286
  53. Schnaubelt S, Niederdöckl J, Simon A, et al. Hemodynamic effects of vernakalant in cardio-surgical ICU-patients treated for recent-onset postoperative atrial fibrillation. Sci Rep. 2020;10(1):1–7. doi:10.1038/s41598-020-64001-8
  54. Shibata SC, Uchiyama A, Ohta N, Fujino Y. Efficacy and safety of landiolol compared to amiodarone for the management of postoperative atrial fibrillation in intensive care patients. J Cardiothorac Vasc Anesth. 2016;30(2):418–422. doi:10.1053/j.jvca.2015.09.007
  55. Simon A, Niederdoeckl J, Skyllouriotis E, et al. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: A randomized controlled trial at the emergency department. Europace. 2017;19(2):233–240. doi:10.1093/europace/euw052
  56. Simopoulos V, Hevas A, Hatziefthimiou A, et al. Amiodarone plus ranolazine for conversion of post-cardiac surgery atrial fibrillation: Enhanced effectiveness in reduced versus preserved ejection fraction patients. Cardiovasc Drugs Ther. 2018;32(6):559–565. doi:10.1007/s10557-018-6832-8
  57. Stefatos A, Ha JN, Baranchuk A, Baldessarini RJ, Vázquez GH. Atrial fibrillation and injected aripiprazole: A case report. Innov Clin Neurosci. 2018;15(5–6):43–45.
  58. Stiell IG, Sivilotti ML, Taljaard M, et al. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): A partial factorial randomised trial. Lancet. 2020;395(10221):339–349. doi:10.1016/S0140-6736(19)32994-0
  59. Stoneman P, Gilligan P, Mahon P, Sheahan R. Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge. Irish J Med Sci (1971–). 2017;186(4):903–908. doi:10.1007/s11845-017-1576-1
  60. Su M, Seki D, Moheet AM. Pharmacologic cardioversion with intravenous amiodarone is likely safe in neurocritically Ill patients. J Clin Neurosci. 2017;39:59–61. doi:10.1016/j.jocn.2017.01.014
  61. Tsanaxidis N, Aidonidis I, Hatziefthimiou A, et al. Ranolazine added to amiodarone facilitates earlier conversion of atrial fibrillation compared to amiodarone‐only therapy. Pacing Clin Electrophysiol. 2017;40(4):372–378. doi:10.1111/pace.13048
  62. Urtubia PA, Carbonell TM. Vernakalant for atrial fibrilation in an emergency department [in Spanish]. Emergencias. 2016;28(1):69. PMID: 29094833
  63. Vinson DR, Lugovskaya N, Warton EM, et al. Ibutilide effectiveness and safety in the cardioversion of atrial fibrillation and flutter in the community emergency department. Ann Emerg Med. 2018;71(1):96–108. doi:10.1016/j.annemergmed.2017.07.481
  64. Vogiatzis I, Papavasiliou E, Dapcevitch I, Pittas S, Koulouris E. Vernakalant versus ibutilide for immediate conversion of recent-onset atrial fibrillation. Hippokratia. 2017;21(2):67–73. PMID:30455558
  65. Wu D, Wu J, Chen M, Ji C, Xu M. Transient new-onset atrial fibrillation during general thoracic operations and its treatment with amiodarone: A retrospective analysis in a single centre. Interact Cardiovasc Thorac Surg. 2019;28(2):227–234. doi:10.1093/icvts/ivy214
  66. Wybraniec MT, Wrobel W, Wilkosz K, Wrona K, Bula K, Mizia‐Stec K. Pharmacological cardioversion with antazoline in atrial fibrillation: The results of the CANT study. J Am Heart Assoc. 2018;7(20):e010153. doi:10.1161/JAHA.118.010153
  67. Yarlagadda B, Vuddanda V, Dar T, et al. Safety and efficacy of inpatient initiation of dofetilide versus sotalol for atrial fibrillation. J Atr Fibrillation. 2017;10(4):1805. doi:10.4022/jafib.1805
  68. Zeemering S, Lankveld TA, Bonizzi P, et al. The electrocardiogram as a predictor of successful pharmacological cardioversion and progression of atrial fibrillation. Europace. 2018;20(7):e96–e104. doi:10.1093/europace/eux234
  69. Zeriouh M, Sabashnikov A, Choi YH, et al. A novel treatment strategy of new onset atrial fibrillation after cardiac surgery: An observational prospective study. J Cardiothorac Surg. 2014;9(1):83. doi:10.1186/1749-8090-9-83
  70. Zhang N, Tse G, Dahal S, et al. Efficacy of Wenxin Keli plus amiodarone versus amiodarone monotherapy in treating recent-onset atrial fibrillation. Cardiol Res Pract. 2018;2018:6047271. doi:10.1155/2018/6047271
  71. Zheng H, Zhu F, Miao P, Mao Z, Redfearn DP, Cao RY. Antimicrobial natural product berberine is efficacious for the treatment of atrial fibrillation. Biomed Res Int. 2017;2017:3146791. doi:10.1155/2017/3146791
  72. Kline SR, Dreifus LS, Watanabe Y, McGarry TF, Likoff W. Evaluation of the antiarrhythmic properties of antazoline: A preliminary study. Am J Cardiol. 1962;9(4):564–567. doi:10.1016/0002-9149(62)90075-9
  73. Kehler JG, Gehring DA. Conversion of atrial fibrillation with antazoline hydrochloride (arithmin). Angiology. 1970;21(1):11–17. doi:10.1177/000331977002100104
  74. Srzednicki M, Sadowski Z, Kulikowski A. Evaluation of the anti-arrhythmia effectiveness of Phenazolinum Polfa in paroxysmal atrial fibrillation [in Polish]. Pol Tyg Lek. 1990;45(45–46):924–927.
  75. Kuch M, Janiszewski M, Dluzniewski M. Antazoline: Ineffective or misprized in the treatment of paroxysmal atrial fibrillation. Pol J Cardiol. 2000;3:247–251.
  76. Pejska M, Kozłowski D, Homenda W, Drapella A. The assessment of the antazoline in conversion atrial fibrillation for the patients over sixty. Geriatr Pol. 2005;1(4):7–11.
  77. Piotrowski R, Kryński T, Baran J, Futyma P, Stec S, Kułakowski P. Antazoline for rapid termination of atrial fibrillation during ablation of accessory pathways. Cardiol J. 2014;21(3):299–303. doi:10.5603/CJ.a2013.0121
  78. Drugs.com. Antazoline. https://www.drugs.com/international/antazoline.html. Accessed September 22, 2020.
  79. Abadie BQ, Hansen B, Walker J, et al. Likelihood of spontaneous cardioversion of atrial fibrillation using a conservative management strategy among patients presenting to the emergency department. Am J Cardiol. 2019;124(10):1534–1539. doi:10.1016/j.amjcard.2019.08.017
  80. Vinson DR, Hoehn T, Graber DJ, Williams TM. Managing emergency department patients with recent-onset atrial fibrillation. J Emerg Med. 2012;42(2):139–148. doi:10.1016/j.jemermed.2010.05.017
  81. Weigner MJ, Caulfield TA, Danias PG, Silverman DI, Manning WJ. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997;126(8):615–620. doi:10.7326/0003-4819-126-8-199704150-00005
  82. Heidbuchel H, Dagres N, Antz M, et al. Major knowledge gaps and system barriers to guideline implementation among European physicians treating patients with atrial fibrillation: A European Society of Cardiology international educational needs assessment. Europace. 2018;20(12):1919–1928. doi:10.1093/europace/euy039
© Wroclaw Medical University